Search

Beam Therapeutics Inc

Closed

SectorHealthcare

25.14 -2.67

Overview

Share price change

24h

Current

Min

24.9

Max

25.32

Key metrics

By Trading Economics

Income

-339M

-94M

Sales

-82M

32M

EPS

-0.91

Profit margin

-297.177

Employees

522

EBITDA

-349M

-89M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+110.8% upside

Dividends

By Acuity

Next Earnings

4 sie 2026

Market Stats

By TradingEconomics

Market Cap

-292M

2.8B

Previous open

27.81

Previous close

25.14

News Sentiment

By Acuity

80%

20%

311 / 340 Ranking in Healthcare

Beam Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lip 2026, 19:26 UTC

Event
Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23 lip 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22 lip 2026, 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21 lip 2026, 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20 lip 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Peer Comparison

Price change

Beam Therapeutics Inc Forecast

Price Target

By TipRanks

110.8% upside

12 Months Forecast

Average 52.91 USD  110.8%

High 80 USD

Low 26 USD

Based on 11 Wall Street analysts offering 12 month price targets forBeam Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Sentiment

By Acuity

311 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat